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Abstract 
Background: Actinic prurigo (AP) is a type of photodermatosis, the pathophysiology of which has not been de-
termined. AP has been suggested to be a hypersensitivity reaction to the presence of eosinophils and the local 
production of IgE. 
Material and Methods: Descriptive study, using paraffin blocks of tissue that have been diagnosed with AP from 
the Dermopathology department, Hospital General Dr. Manuel Gea González. In 66 blocks from 63 patients, eosi-
nophils were identified by hematoxylin and eosin staining, and mastocytes were labeled by immunohistochemistry. 
Three random microphotographs (40x) were used, and cell counts were calculated as the mean count in the 3 mi-
crophotographs. 
Results: Forty cases (63.5%) were female, and 23 (36.5%) were male. The mean age was 26.49 ±14.09 years; 
regarding the evolution time of the disease, the average was 11.93 years ±11.39. In 38 of 63 cases (60%), the lip, 
skin, and conjunctiva were affected clinically. In 22 of 63 cases (34%), AP cheilitis was the sole manifestation, and 
in 4 of 63 cases (6%), there were lesions in the skin and conjunctiva. The mean eosinophil count was 9 per case, the 
average number of mastocytes/field was 28.48 (range 0 to 66)  Kruskal-Wallis p=0.001. 
Conclusions: There are elements in AP that mediate the reaction of hypersensitivity type IV b, necessitating the 
identification of triggering factors.
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Introduction
Actinic prurigo (AP) is a chronic, inflammatory pho-
todermatosis that affects the skin, lip, and conjunctival 
mucosa. AP primarily affects mixed-race and Amerin-
dian populations who generally express the HLA-DR4 
subtype DRB1*0407 allele (1-6) and live at altitudes 
over 1000 m above sea level (7). 
AP usually develops in infancy and predominates in fe-
males up 4:1, (8-11) affecting photoexposed areas. Cli-
nically, erythematous papules, excoriation, and hematic 
scabs that form plaques are observed; pruritus develops, 
causing areas of lichenification (9-11). Cheilitis is pre-
sent in nearly 85% of AP cases, and in 27% of cases, it is 
the sole manifestation of the illness (12). 
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Between 45% and 62% of AP patients present with con-
junctivitis and pseudopterygium formation (7,8,10). It 
evolves chronically, with partial remission (13). By histo-
pathology, epithelial acanthosis, spongiosis and exulce-
ration, and an abundance of eosinophils are seen in the 
dermis, and there is an infiltrate of nodular lymphoplas-
mocytes that can form lymphoid follicles, patognomonic 
image of AP´s chelitis (14,15). Dendritic follicular cells 
and plasma IgE-producing cells are also present, and IL-2 
is produced by B and T lymphocytes (16). Elevated serum 
IgE has been reported in 10% to 50% of patients with AP 
and peripheral eosinophilia (17).
Ultraviolet radiation in AP, (18-22) effecting local lym-
phocyte proliferation through the secretion of soluble 
compounds by keratinocytes, with no change in serum 
leucocyte levels (23-25).
Mastocytes participate in inflammatory and allergic 
reactions. They are activated primarily through the high-
affinity IgE receptor (FcεRI), which can bind the IgE-
antigen complex to initiate a complex transduction of 
signals that culminate in the secretion of proinflamma-
tory mediators and cytokines. 
Other mechanisms include anaphylatoxins that genera-
ted by activation of the complement pathway, bacteria 
through Toll-like receptors, the release of TNF-α by 
mastocytes that amplify a stimulus, and T lymphocyte 
stimulation (26-29).
The presence of IgE-expressing eosinophils and mas-
tocytes implicates a hypersensitivity reaction in the pa-
thophysiology of AP (30). Generally, hypersensitivity 
reactions occur on exposure to an antigen through the 
activation of effector cells. There are 4 types of hyper-
sensitivity reactions according the Gell and Coombs 
classification (31,32). 
Hypersensitivity reaction type IV, or retarded reaction, is 
mediated specifically by T lymphocytes, which produce 
cytokines that activate various antibodies. The IVa sub-
type corresponds to a Th1 response, which stimulates 
macrophages by secreting IFNy in which complement-
fixing antibodies and complement isotypes are co stimu-
lants of proinflammatory and CD8 cells. 
Conversely, the subtype IVb initiates a Th2 immune 
response in which lymphocytes T secrete IL-4, IL-5, 
and IL-13, which, through B cells that produce IgE and 
IgG4, stimulate eosinophils and mastocytes and inacti-
vate macrophages. The high production of IL-5 causes 
eosinophilic inflammation, a characteristic of type IV 
hypersensitivity reactions (33-37).  
The aim of this study was to examine the presence of 
mast cells and eosinophils in AP to increase our unders-
tanding of its pathophysiology.
Material and Methods 
This descriptive study we performed in the Dermopa-
thology Department of Hospital General Dr. Manuel 
Gea González. The study samples were obtained from a 
pool of 40 tissue samples in skin with prurigo through a 
search of paraffin blocks using the clinical and histolo-
gical criteria of AP. 
From this database, we drew the demographics and cha-
racteristics of the patients whose tissues were included 
(sex, age, clinical localization, family records, and evo-
lution time of the disease). 
Using H&E slides for all cases, the diagnosis of AP was 
confirmed, and the presence of eosinophils and masto-
cytes was examined. The tissue block were, then slice 
and processed by immunohistochemistry. The tissues 
were deparaffinized, rehydrated, and subjected to anti-
genic recovery with 0.1% sodium citrate, pH 6.2, en-
dogen peroxidase was inactivated (0.9% hydrogen pe-
roxide), and the slides were incubated with 1% bovine 
serum albumin to block nonspecific sites. Washes were 
performed with PBS. 
Tissues were incubated for 45 minutes with polyclonal 
anti-CD 117 (Dako1:50), after which anti-mouse/anti-
rabbit secondary antibody was applied. Streptavidin-pe-
roxidase complex was added to the slides for 30 minutes, 
and the reactions were visualized with diaminobenzidine 
(Dako) and counterstained with Hills´ hematoxylin. 
The positive controls comprised 8 paraffin blocks of 
biopsies from various patients-2 healthy mucosal sam-
ples and 1 of each of the following: mucocele, venous 
lake, fibrous hyperplasia, traumatic cheilitis, sclerotic 
lichen, and granulomatous cheilitis.
Eosinophil counts and immunohistochemistry evalua-
tion were performed semi-quantitative, based on posi-
tivity to anti-CD 117 (Dako1:50) in the membrane and 
cytoplasm of mastocytes. Three 40x microphotographs 
were selected randomly for H&E staining for eosino-
phils and immunohistochemistry for mastocytes, all 
of them with and cells of 5x4, which include a surface 
of 0.3mm2. Counting of the cells present in each of the 
cells was performed and it was added respectively so the 
number of the total positive cells was able to be known 
in the whole image. Average counts were calculated over 
the 3 microphotographs. 
Results
Sixty-six blocks of tissue with a diagnosis of AP or AP 
cheilitis were selected. They had been diagnosed bet-
ween 1995 and 2006 and contained enough biological 
material to be included in the study. 
Forty cases (63.5%) were female, and 23 (36.5%) were 
male. The mean age was 26.49±14.09 (range 7-63 
years). 
The mean time in which the AP developed was 11.93 
years ±11.39; time from diagnosis of AP ranged from 6 
months to 45 years. Twenty-three patients (36.5%) had 
any immediate family member with a history of AP.
In 38 of 63 (60%) cases, the lip, skin, and conjuntiva 
J Clin Exp Dent. 2015;7(5):e656-9.                                                                                                                                                             Inmunohistochemical detection of mastocytes
e658
were clinically affected; in 22 cases (34%), AP cheilitis 
was the sole manifestation (only used for the study tis-
sue of AP located in skin). Four cases (6%) had lesions 
in the skin and conjunctiva but not in the lip. 
In the 66 tissue samples that were diagnosed with AP 
and stained with H&E, the average number of eosino-
phils was 9 per case (Fig. 1). The average number of 
mastocytes in the mucosa of patients with AP was 28.48/
field, ranging from 0 to 66 (Table 1), versus 9.75/field in 
the control groups (range 5 to 16) and 7 mastocytes/field 
in healthy mucosa (Kruskal-Wallis p=0.001). 
Figure 2 shows representative immunohistochemistry 
staining of a randomly selected field. There were no 
significant differences in evolution time of disease or 
mean number of mastocytes per field. By calculation of 
Pearson´s correlation coefficient, we did not observe any 
linear relationship between mastocytes number and the 
evolution time of the disease (Table 2) or between eosi-
nophil number and the number of positive mastocytes. 
Fig. 1. (HyE 40x) Presence of eosinophils in tissue with AP. Three 
micrographs were analyzed for each case, and the average of the 3 
images was calculated.
# Positive 
Mastocytes
#Cases
(n)
0 3
1-10 1
11-20 13
21-30 25
31-40 16
41-50 6
51-60 1
61-70 1
Table 1. Number of positive mas-
tocytes in AP samples.
Fig. 2. Membrane and cytoplasmic reaction of anti-CD117 in tis-
sue with AP in skin.
Evolution 
time (years)
Positive
Cases
%
0-5 17 26.99
6-10 17 26.99
11-15 4 6.34
16-20 3 4.76
21-25 7 11.11
26-30 7 11.11
>31 8 12.70
Table 2. Evolution time of AP and number of 
positive mastocytes.
Discussion
Actinic prurigo occurs predominantly in women. 
Although the first signs of which develop in childhood, 
patients are usually diagnosed late. At the time that the 
clinical history is taken, it is common to record data on 
any relatives with the disease (7,12-15,38). The charac-
teristics of our study sample—a predominance of fema-
le patients, early age of onset (mean 14.35 years), and 
36.3% of patients with a family history of PA-are con-
sistent with these rates.
The number of mastocytes in normal skin increases from 
44 to 75 mastocytes/mm2 and has an irregular distribution 
throughout the body, concentrating in the acral areas (39). 
In contrast, our AP patients had 189 mastocytes/mm2 at an 
enlargement of 40x and with a surface of 0.3 mm2.
The density of mastocytes per field was greater in muco-
sa of patients with AP versus healthy mucosa and other 
lesions, including those with an inflammatory origin, 
implicating these cells in the pathophysiology of AP. 
In contrast, there were no significant differences in the 
quantity of mastocytes or time of evolution. 
Previous studies have reported the predominance of a 
Th2 response in AP, leading to the hypothesis that AP 
was a type I hypersensitivity reaction. In recent studies, 
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however, when taking into account the presence of eosi-
nophils, local production of IgE by plasma cells, increa-
se in mastocytes number, detection of B and T cells, and 
participation of IL-2, an updated model suggests that the 
pathophysiology of AP is based on a type IV hypersensi-
tivity reaction- specifically, subtype b-although subtype 
a can not be dismissed completely, based on these fin-
dings (16,24,36,39-41).
Future studies should attempt to identify an antigen that, 
with exposure to ultraviolet light, triggers an inflammatory 
reaction and leads to the clinical manifestations of AP.
Conclusions 
The higher density of mastocytes in samples from patients 
with actinic prurigo confirms the presence of all of the 
principal elements that mediate the reaction of late hyper-
sensitivity type IV b, prompting us to hypothesize about 
the existence of a triggering allergen. More studies are re-
quired to resolve the pathophysiology of AP-specifically 
with regard to IL-2, IL-4, IL-5, and NK cells-and determi-
ne if and which apoptotic pathways are involved. 
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